Results 151 to 160 of about 49,566 (218)

Combination Therapy for Chronic Hepatitis B: Current Indications [PDF]

, 2011
Navin Paul, Steven-Huy Han
core   +1 more source

Serum N-glycomics for non-invasive detection of significant liver pathology across clinical phases of treatment-naïve chronic hepatitis B. [PDF]

J Transl Med
Li X, Shi M, Yu H, Huang J, Ji S, Han B, Zhong Y, Kang P, Zhang Y, Chen C, Zhang C, Xu L, Chi X, Shen T.   +13 more
europepmc   +1 more source

Genotype-specific Response to 144-week Entecavir Therapy for HBeAg-positive Chronic Hepatitis B with a Particular Focus on Histological Improvement: A Prospective Study. [PDF]

J Clin Transl Hepatol
Liu L, Xu Q, Lin S, Wei Z, Huang G.
europepmc   +1 more source

Expression and significance of INTS10 and IRF3 in chronic hepatitis B patients. [PDF]

Front Microbiol
Ye A, Chen X, Qiu D, Wu W.
europepmc   +1 more source

Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.

Journal of Antimicrobial Chemotherapy, 2015
M. Machaira, V. Papaevangelou, E. Vouloumanou, G. Tansarli, M. Falagas   +4 more
semanticscholar   +1 more source

Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review. [PDF]

Infect Dis Ther
Sun HM, Wang XY, Xu HQ, Gao YH.
europepmc   +1 more source

Orthotopic liver transplantation: Indications and results [PDF]

, 1995
Aldrighetti, LA, Doyle, HR, Marino, IR, Starzl, TE   +3 more
core  

Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment

Antimicrobial Agents and Chemotherapy, 2015
Guo-Jun Li, Yiqi Yu, Shaolong Chen, P. Fan, L. Shao, Jia-Zhen Chen, C. Li, Bin Yi, Wei-Cun Chen, S. Xie, Xiaona Mao, H. Zou, Wenhong Zhang   +12 more
semanticscholar   +1 more source

New Insights into the Role of NF-κB in Hepatitis B Virus Infection. [PDF]

Int J Biol Sci
Halemubieke S, Liu X, Yan Y, Ji H, Sun H, Ma J, Chang L, Wang L.   +7 more
europepmc   +1 more source

Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical <i>in vivo</i> models. [PDF]

Antimicrob Agents Chemother
Noack J, Anglero-Rodriguez Y, Gall J, Zhou J, LeBlanc S, Liebow A, Bakardjiev A, Hebner CM, Purcell LA, Jadhav V, Corti D, Lempp FA.   +11 more
europepmc   +1 more source